GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadimastem Ltd (XTAE:KDST) » Definitions » EV-to-Revenue

Kadimastem (XTAE:KDST) EV-to-Revenue : (As of Apr. 28, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Kadimastem EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Kadimastem's enterprise value is ₪22.92 Mil. Kadimastem's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.00 Mil. Therefore, Kadimastem's EV-to-Revenue for today is .

The historical rank and industry rank for Kadimastem's EV-to-Revenue or its related term are showing as below:

During the past 11 years, the highest EV-to-Revenue of Kadimastem was 701.44. The lowest was -11.15. And the median was 9.40.

XTAE:KDST's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.66
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-28), Kadimastem's stock price is ₪4.947. Kadimastem's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.00. Therefore, Kadimastem's PS Ratio for today is .


Kadimastem EV-to-Revenue Historical Data

The historical data trend for Kadimastem's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadimastem EV-to-Revenue Chart

Kadimastem Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Kadimastem Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kadimastem's EV-to-Revenue

For the Biotechnology subindustry, Kadimastem's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kadimastem's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kadimastem's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Kadimastem's EV-to-Revenue falls into.



Kadimastem EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Kadimastem's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=22.915/0
=

Kadimastem's current Enterprise Value is ₪22.92 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kadimastem's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kadimastem  (XTAE:KDST) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Kadimastem's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=4.947/0
=

Kadimastem's share price for today is ₪4.947.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kadimastem EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Kadimastem's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Kadimastem (XTAE:KDST) Business Description

Traded in Other Exchanges
Address
Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona, ISR
Kadimastem Ltd is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. It is developing revolutionary regenerative therapies based on stem cells.

Kadimastem (XTAE:KDST) Headlines

No Headlines